We are international
Donate
TEXT SIZE   


Phase III VELCADE® Clinical Trials
05.01.08

US TRIALS

  • UARK 2006-66, Total Therapy 3B: An extension of UARK 2003-33 Total Therapy (2006-66)
    Little Rock, AR

  • UARK 2006-15: A Study of Tandem Transplants with or without Bortezomib and Thalidomide (2006-15)
    Little Rock, AR

  • Study of multiple myeloma patients relapsing or progressing after autologous transplantation on Total Therapy 2 (2006-05)
    Little Rock, AR

  • Phase III Randomized Study of Melphalan and Prednisone with versus without Bortezomib in older patients with newly diagnosed multiple myeloma (UCLA-0409110-01)
    Los Angeles, CA

  • Randomized Phase IIIb study of three treatment regimens in subjects with previously untreated multiple myeloma who are not considered candidates for high-dose chemotherapy and autologous stem cell transplantation: VELCADE (bortezomib), thalidomide, and dexamethasone (VTD) versus VELCADE, melphalan, and prednisone (MVP) ((UPFRONT)C05009)
    New York, NY - multicenter

  • Phase III Randomized Study of Consolidation Therapy Comprising Bortezomib and Dexamethasone with versus without Lenalidomide in patients with symptomatic multiple myeloma who have completed a Dexamethasone-based induction regimen (E1A05)
    Philadelphia, PA

  • A Study of Tanespimycin (KOS-953) in patients with multiple myeloma in first relapse (KAG-301)
    multicenter

  • Phase III Randomized Study of Lenalidomide and Low-Dose Dexamethasone with versus without Bortezomib in Patients With Previously Untreated Multiple Myeloma (SWOG-S0777)
    multicenter

FOREIGN TRIALS

  • Bortezomib-doxorubicin-dexamethasone (BDD) as treatment for patients with multiple myeloma presenting with acute renal failure (VEL-EU-0038)
    Vienna, Austria

  • Efficacy of Bortezomib Consolidation After High-Dose Melphalan With Stem Cell Support in Myeloma Patients (NMSG 15/05)
    Copenhagen, Denmark - multicenter

  • VELCADE and melphalan combination conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma patients younger than 65 (2007-VEL-EU-0004)
    Toulouse, France - multicenter

  • Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma (CR006127)
    Germany - multicenter

  • Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma Age < 60 Years (CR006124)
    Germany - multicenter

  • A Phase III, multi-center randomized open label study of VELCADE/melphalan/prednisone and thalidomide (V-MPT) versus VELCADE/melphalan/prednisone (V-MP) in elderly untreated multiple myeloma patients (ITA-IIS-VEL-2005-11)
    Torino, Italy - multicenter

  • VELCADE plus cyclophosphamide, dexamethasone, thalidomide (V-CDT) as induction therapy for newly diagnosed myeloma patients who are autograft candidates (2006-VEL-AP-0021)
    Malaysia

  • A randomized controlled study of VELCADE (bortezomib) plus thalidomide plus dexamethasone compared to thalidomide plus dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation (X05140)
    Leiden, Netherlands - multicenter

  • A randomized Phase III study on the effect of bortezomib combined with adriamycin, dexamethasone (AD) for induction treatment, followed by high-dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma (HOVON X05164)
    Rotterdam, Netherlands - multicenter (ongoing site enrollment)

  • Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed myeloma following allogeneic stem cell transplantation (2006-VEL-EU-0025)
    Utrecht, Netherlands - multicenter

  • VTD (VELCADE, thalidomide, and dexamethasone) induction followed by MPT maintenance for multiple myeloma (age > 65) (VEL-AP-0046)
    Incheon, South Korea

  • Sequential VAD (vincristin, adriamycin, and dexamethasone) and VTD (VELCADE, thalidomide, and dexamethasone) induction chemotherapy followed by high-dose therapy with autologous stem cell transplantation and maintenance therapy with VELCADE for newly diagnosed multiple myeloma (VEL-AP-0045)
    Seoul, South Korea

  • A national, open-label, multi-center, randomized comparative Phase III study of VBMCP-VBAD/VELCADE versus thalidomide/dexamethasone versus VELCADE/thalidomide/dexamethasone followed by high dose intensive therapy with autologous hemopoietic stem cell (VEL-EU-0027)
    Salamanca, Spain

  • A national, open-label, multi-center, randomized comparative Phase III study of VELCADE/melphalan/prednisone versus VELCADE/thalidomide/prednisone and maintenance treatment with thalidomide versus prednisone in elderly untreated patients with mutliple myeloma (VEL-EU-0031)
    Salamanca, Spain - multicenter

  • GEM05 for Patients With Multiple Myeloma More Than 65 Years Old (2005-001111-21)
    Spain - multicenter

  • GEM05 for Patients With Multiple Myeloma Under 65 Years (2005-001110-41)
    Spain - multicenter

  • Bortezomib consolidation in patients with myeloma following treatment with high-dose melphalan and autologous stem cell support. (VEL-EU-0083)
    Gothenburg, Sweden - multicenter

  • VELCADE, idarubicin and melphalan in patients with refractory/relapsed multiple myeloma (VEL-03-095)
    Leeds, UK - multicenter

  • First amendment to Myeloma IX study: Bortezomib and dexamethasone in relapse (UK-VEL-13)
    Leeds, UK - multicenter


 related articles